IO Biotech (NASDAQ:IOBT – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, Zacks.com reports. The firm currently has a $5.75 price target on the stock. Zacks Investment Research‘s price target would suggest a potential upside of 20.04% from the stock’s current price.
According to Zacks, “IO Biotech Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel, immune-modulating cancer therapies based on its T-win(R) technology platform. IO Biotech Inc. is based in WILMINGTON, Del. “
NASDAQ:IOBT opened at $4.79 on Tuesday. IO Biotech has a one year low of $3.56 and a one year high of $17.88. The stock has a 50-day simple moving average of $6.58 and a 200 day simple moving average of $7.09.
A number of hedge funds and other institutional investors have recently modified their holdings of IOBT. Ergoteles LLC bought a new stake in shares of IO Biotech during the first quarter valued at approximately $59,000. Stifel Financial Corp bought a new stake in shares of IO Biotech during the fourth quarter valued at approximately $64,000. Bank of America Corp DE bought a new stake in shares of IO Biotech during the fourth quarter valued at approximately $64,000. Geode Capital Management LLC bought a new stake in shares of IO Biotech during the fourth quarter valued at approximately $73,000. Finally, Jane Street Group LLC bought a new stake in shares of IO Biotech during the first quarter valued at approximately $76,000. 52.20% of the stock is currently owned by hedge funds and other institutional investors.
IO Biotech Company Profile (Get Rating)
IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
- Get a free copy of the StockNews.com research report on IO Biotech (IOBT)
- MarketBeat Podcast: Is Staying the Course Still The Best Investing Strategy?
- CrowdStrike earnings and revenue beat forecasts, stock falls
- Ryder System, Inc: The Most Interesting Play In Logistics
- This Isn’t A Buyable Bottom For Stocks
- Macys Stock is Ready to Buy
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for IO Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IO Biotech and related companies with MarketBeat.com's FREE daily email newsletter.